Abstract 318: Heart Failure and Osteoporosis- an Evidence Based Approach

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Anmol Kapoor ◽  
Amanpreet Singh ◽  
Armandeep Singh

Background: Heart disease occurs when there is reduced blood flow to the heart. It refers to a range of conditions that affect the heart. These conditions include ischemic heart disease (which can lead to acute myocardial infarction), angina, arrhythmia, atrial fibrillation, and heart failure, among others. Currently, there are 600,000 Canadians living with heart failure (HF) with 50,000 Canadians being diagnosed every year with HF. Community-based heart failure clinics have been proven to reduce hospitalizations, but Alberta has only one. The CHARM (Community Heart Failure Assessment, Rehabilitation and Management) clinic at Advanced Cardiology, Calgary, Alberta is a community based, charity funded clinic providing outpatient care, which is physician-directed but RN managed. We intended to investigate whether there was any relationship between patients with heart failure and their pre-disposition to osteoporosis and vice versa. Methods: We performed an observational case series with a retrospective chart review of 600 CHARM clinic patients who have been diagnosed with Heart Failure till June 2019. The primary endpoint was to look at CHARM clinic's prevalence of HF, patients who ever had Bone Mineral Density (BMD) done and if there was an intertwining relationship by comparing co-existence of heart failure with osteoporosis. Results: •Total # of pts above 65 years of age from a pool of 356 clinic pts = 169•Total # of pts above 65 years of age who had BMD done before June 2019 = 60•Total # of pts above 65 years of age who have Not had BMD done before June 2019 =108•Percentage of patients above 65 years of age who had BMD done before June 2019 = 35%•Percentage of patients above 65 years of age who have not had BMD done before June 2019 = 65%We also compared our finding with studies from Raymond b. Et al and Ezekowitz and it was found that out of 623 patients with Heart failure, 12% had moderate to severe vertebral compression fracture, 55% of those people have multiple fractures. It was seen that CHF patients with osteoporosis were the features that they were mostly female, Caucasian, smoker, obese, hypertensive, COPD, and patients with prevalence of diabetes. Conclusion: It was noticed from our clinic data that 65% of the patients with CHF did not have a BMD done (till June2019) and there by the presence of osteoporosis could have gone undiagnosed. What complicates CHF and osteoporosis is the age factor (mostly elderly), shared risk factors(factors include advanced age, hypovitaminosis D, renal disease and diabetes mellitus), medication use like (loop diuretics) and common pathogenic mechanisms(activation of the renin-angiotensin-aldosterone system) affect both HF and osteoporosis. It is to be noted that CHF is a major risk factor for mortality following fracture as the patient becomes immobile and it is important to carefully assess osteoporosis and take measures to reduce the risk of osteoporotic fractures.

2015 ◽  
Vol 178 ◽  
pp. 268-274 ◽  
Author(s):  
Stephanie James ◽  
David Barton ◽  
Eoin O'Connell ◽  
Victor Voon ◽  
Gillian Murtagh ◽  
...  

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Mohammed Ruzieh ◽  
Aaron Baugh ◽  
lama jebbawi ◽  
Andrew J Foy

Introduction: In patients with heart failure (HF) and ischemic heart disease (IHD), beta-blockers (BB) are associated with improved mortality. However, in patients with co-morbid chronic obstructive pulmonary disease (COPD), this drug class is less utilized due to concerns about an unfavorable impact on the morbidity and mortality. Patients with COPD and heart disease have higher mortality than those with heart disease alone. There is a need to clarify the safety of BB in this population. Objective: To assess the effect of BB therapy on mortality in patients with heart disease and COPD. Methods: We performed a systematic search of MEDLINE and PubMed inception until May 30, 2020 to identify articles of BB use in patients with COPD. The risk ratio (RR) of mortality with BB use was calculated using the Mantel Haenszel random effect model. Statistical analysis was performed using Review Manager Web (RevMan Web). A two-sided p value of < 0.05 was considered statistically significant. Results: A total of 16 studies were included in this meta-analysis, comprising 133,538 patients (44,893 received BB, 88,381 received no control drug, and 264 received placebo). BB use was associated with reduced risk of mortality overall (14.8% vs. 19.9%, RR: 0.67, 95% CI: 0.57 - 0.79), in patients with IHD (18.6% vs. 26.6%, RR: 0.64, 95% CI: 0.50 - 0.82), and in patients with HF (8.1% vs. 23.6%, RR: 0.56, 95% CI: 0.41 - 0.75), Figure. BB were used to treat hypertension in one study, and it was associated with reduced risk of mortality (6.2% vs. 13.4%, RR: 0.46, 95% CI: 0.28 - 0.78). In contrast, βB use was not associated with statistically significant reduced risk of mortality when given without a specified cardiovascular indication (25.0% vs. 32.5%, RR: 0.82, 95% CI: 0.59 - 1.15), figure. Conclusion: Beta-blockers are associated with improved mortality in patients with HF or IHD and COPD. A diagnosis of COPD should not preclude treatment with beta-blockers, as previous concerns likely over-stated risk.


2020 ◽  
Vol 4 (3) ◽  
pp. 1-6
Author(s):  
James Cranley ◽  
Antonia Hardiman ◽  
Leisa J Freeman

Abstract Background Levosimendan is a non-adrenergic calcium-sensitizing agent with positive inotropic and vasodilatory effects. Its use in acute decompensation of heart failure is established. Good evidence now exists for repetitive infusions of Levosimendan to improve symptoms and reduce hospitalization in advanced heart failure (AdHF) populations. Its use in heart failure resulting from congenital heart disease is not yet commonplace. Case summary We present three cases in which pulsed Levosimendan was used in the management of AdHF secondary to underlying congenital heart disease. There was symptomatic and biomarker evidence of improvement. Discussion Intermittent Levosimendan may represent a valuable therapy to reduce hospitalization and improve quality of life in adults with congenital heart conditions.


2019 ◽  
Vol 8 (1) ◽  
pp. 48-52
Author(s):  
Abdul Khaliq Monib ◽  
Sahadeb Prasad Dhungana ◽  
Rajesh Nepal ◽  
Rinku Ghimire

Background: There is limited information on the clinical profile of patients with heart failure from the Nepalese population. Materials and Methods: This is a descriptive cross-sectional study on 120 consecutive patients with New York Heart Association class II or IV symptoms of heart failure admitted from June 2018 to January 2019 at Nobel Medical College Teaching hospital, Biratnagar, Nepal. Results: Mean age was 52.2 ± 20.6 years. The male and female ratio was 0.71. Ischemic cardiomyopathy, rheumatic heart disease, dilated cardiomyopathy, acute coronary syndrome, hypertensive heart disease, and peripartum cardiomyopathy were common etiologies constituting 22.5%, 19.1%,13.3%, 9.1%, 8.3 %, 5% of cases respectively. Among co-morbid conditions, anemia (91.6%),hypertension (31.6%), coronary artery disease (29.1%), diabetes (20.8%) and chronic kidney disease (11.6%) were common. Among various drugs used, 66.6% patients were prescribed diuretics, 60% mineral corticoid receptor blockers, 33.3% angiotensin-converting enzymeinhibitors, 33.3% beta-blockers, 29.1% digoxin and 8.3% angiotensin receptor blockers. Echocardiography revealed LV systolic and diastolic dysfunction in 75% and 25% respectively, mitral regurgitation in 52.5%, right ventricular dysfunction in 10.8 % and pulmonary artery hypertension in 66.6%. Conclusion: Appropriate use of evidence-based therapies, careful attention to the diagnosis and management of specific co-morbidities in patients with HF may help to improve outcomes.


Sign in / Sign up

Export Citation Format

Share Document